Literature DB >> 10583015

Acetylcholinesterase inhibitors in Alzheimer's disease.

B M McGleenon1, K B Dynan, A P Passmore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10583015      PMCID： PMC2014378          DOI： 10.1046/j.1365-2125.1999.00026.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  39 in total

Review 1.  Advances in Alzheimer's disease.

Authors:  R Katzman; T Saitoh
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

2.  Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.

Authors:  E Kramer-Ginsberg; R C Mohs; M Aryan; D Lobel; J Silverman; M Davidson; K L Davis
Journal:  Psychopharmacol Bull       Date:  1988

3.  Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature.

Authors:  A F Jorm
Journal:  Aust N Z J Psychiatry       Date:  1986-06       Impact factor: 5.744

4.  Tacrine in Alzheimer's disease.

Authors:  S A Eagger; R Levy; B J Sahakian
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

5.  Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention.

Authors:  L Berg; J P Miller; J Baty; E H Rubin; J C Morris; G Figiel
Journal:  Ann Neurol       Date:  1992-03       Impact factor: 10.422

6.  Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.

Authors:  W McNally; M Roth; R Young; H Bockbrader; T Chang
Journal:  Pharm Res       Date:  1989-11       Impact factor: 4.200

7.  Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.

Authors:  J A Nielsen; E E Mena; I H Williams; M R Nocerini; D Liston
Journal:  Eur J Pharmacol       Date:  1989-11-28       Impact factor: 4.432

8.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

Authors:  M Farlow; S I Gracon; L A Hershey; K W Lewis; C H Sadowsky; J Dolan-Ureno
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

9.  Measurement of quality-of-life changes in patients with Alzheimer's disease.

Authors:  R DeJong; O W Osterlund; G W Roy
Journal:  Clin Ther       Date:  1989 Jul-Aug       Impact factor: 3.393

10.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112
View more
  67 in total

1.  Drugs for Alzheimer's disease.

Authors:  James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  Wet or dry: translatable "water mazes" for mice and humans.

Authors:  Kerin K Higa; Jared W Young; Mark A Geyer
Journal:  J Clin Invest       Date:  2016-01-19       Impact factor: 14.808

3.  Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.

Authors:  Prajakta P Masurkar; Satabdi Chatterjee; Jeffrey T Sherer; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2021-05-24       Impact factor: 3.923

4.  Inactivation of acetylcholinesterase by various fluorophores.

Authors:  Lilu Guo; Alirica I Suarez; Charles M Thompson
Journal:  J Enzyme Inhib Med Chem       Date:  2010-02       Impact factor: 5.051

Review 5.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

6.  Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.

Authors:  Seema Bag; Sanjukta Ghosh; Rekha Tulsan; Abha Sood; Weihong Zhou; Christine Schifone; Michelle Foster; Harry LeVine; Béla Török; Marianna Török
Journal:  Bioorg Med Chem Lett       Date:  2013-03-14       Impact factor: 2.823

Review 7.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Authors:  Michael W Jann; Kara L Shirley; Gary W Small
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  In Silico Design and Evaluation of Carboxylesterase Inhibitors.

Authors:  Shana V Stoddard; Xiaozhen Yu; Philip M Potter; Randy M Wadkins
Journal:  J Pest Sci (2004)       Date:  2010       Impact factor: 5.918

10.  Nicotine promotes survival of cells expressing amyloid precursor protein and presenilin: implication for Alzheimer's disease.

Authors:  Dwayne Brown; Carlana Ramlochansingh; Kebreten F Manaye; Yousef Tizabi
Journal:  Neurosci Lett       Date:  2013-01-08       Impact factor: 3.046
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.